Detail akcie Rigel Pharma online

Business Summary: Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Rigel Pharmaceuticals Inc revenues decreased 3% to $116.9M. Net loss decreased 57% to $25.1M. Revenues reflect Contract revenues from collaborations decrease of 71% to $11.5M, Government contract decrease of 76% to $1.1M. Lower net loss reflects Research and development - Balancing val decrease of 61% to $22.4M (expense), Stock-based Compensation in SGA decrease of 34% to $6.7M (expense).